Status:
ACTIVE_NOT_RECRUITING
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Metastatic Sarcoma
Recurrent Sarcoma
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
This early phase I trial studies an imaging technique called 68Ga-FAPi-46 PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patie...
Detailed Description
PRIMARY OBJECTIVE: I. To define the biodistribution of gallium Ga 68 fibroblast activation protein inhibitor (FAPi)-46 (68Ga-FAPi-46) in normal and cancer tissues of patients with sarcoma with histop...
Eligibility Criteria
Inclusion
- Patients who are scheduled to undergo surgical excision or biopsy of a suspected sarcoma primary, or a suspected recurrent or metastatic lesion.
- Patients who are ≥ 18 years old at the time of the radiotracer administration.
- Patients who can provide written informed consent.
- Patients who are able to remain still for duration of imaging procedures (up to one hour for each).
Exclusion
- Patient is pregnant or nursing.
- Patients with any new cancer therapy between the baseline 18F-FDG PET/CT and the investigational FAPI PET/CT
- Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high quality data.
Key Trial Info
Start Date :
September 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 21 2027
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04457258
Start Date
September 8 2020
End Date
July 21 2027
Last Update
August 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States, 90095